BioteBTMD
Recorded

Biote 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration30 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this event is being recorded. I would now like to turn the conference over to Szymon Serowiecki, Investor Relations.

Szymon SerowieckiInvestor Relations

Please go ahead. Thank you for joining us today.

Szymon SerowieckiInvestor Relations

This afternoon, Biote published financial results for the third quarter ended September 30, 2026. This news release is available in the Investor Relations section of the company's website. Hosting today's call are Bob Peterson, Interim Chief Executive Officer and Chief Financial Officer, Dr. Komal Bajaj, Chief Medical Officer, and Marc Beer, Executive Chairman. Before we get started, I would like to remind everyone that management will make statements during this call that include forward-looking statements regarding, among other things, the company's financial results and financial condition, future performance and growth opportunities, business outlook, strategic plans and anticipated benefits, goals, research and development, manufacturing and commercialization activities, its competitive position, regulatory process operations, benefits of its solutions, anticipated impact of macroeconomic conditions on its business, and other matters that do not relate to historical facts. These statements are not guarantees of future performance.

Szymon SerowieckiInvestor Relations

They are subject to a variety of risks and uncertainties, some of which are beyond the company's control. Actual results could differ materially from expectations reflected in any forward-looking statements. These statements are subject to risks, uncertainties, and assumptions that are based on management's current expectations as of today. Biote undertakes no obligation to update them in the future. Therefore, these statements should not be relied upon as representing the company's views as of any subsequent date. For a discussion of risks and other important factors that could affect their actual results, please refer to our SEC filings available on the SEC's website and in the Investor Relations section of our website, as well as risks and other important factors discussed in the earnings release. Management also refers to Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures to provide additional information for investors.

Szymon SerowieckiInvestor Relations

A reconciliation of the non-GAAP to GAAP measures is provided in the earnings release, with the primary differences being stock-based compensation, fair value adjustment of certain liabilities, and other non-operating expenses. Please refer to our third quarter 2026 earnings release for a reconciliation of these non-GAAP measures to the closest comparable GAAP measures. I turn the call over to Bob Peterson.

Bob PetersonInterim CEO and CFO

Thanks, Simon, and good afternoon, everyone, and thank you for joining us. While recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated. Last quarter, we discussed our shift from foundational corporate work towards making deeper data-driven operational improvements across our business. That work remains ongoing and is essential to restoring long-term procedure revenue growth. To achieve this, our two immediate priorities remain increasing sales productivity and strengthening practitioner engagement. With respect to productivity, consistent execution at the practice level is key. Retaining clinic relationships, helping new clinics become productive quickly, and supporting practitioners as they build their practices all shape our financial trajectory.

Bob PetersonInterim CEO and CFO

To accelerate our progress and optimize our decision-making, we are leveraging our investments in data and analytics to identify clinics that need additional support so that we can direct our resources where we believe they will have the greatest and most immediate impact. These data-driven insights also guide sales coaching and accountability, helping our team drive improved clinic productivity more consistently. We are measuring the effectiveness of these efforts daily through clinic retention, procedure volume, and sales productivity. Meanwhile, we continue to work on expanding our robust network of clinics. We continue to improve our onboarding efficiency, working more closely with clinics to provide targeted support as they initiate patient treatment. That leads me to our second and equally important priority, deepening practitioner engagement.

Bob PetersonInterim CEO and CFO

At a high level, we know our best practitioners see Biote as a key long-term partner that provides an ongoing source of clinical education and practice-building support. Achieving that objective requires consistent engagement driven by in-person visits, responsive support, and coordination among our teams to address each practice's needs. Successful engagement with our practitioners is about making each interaction highly valuable, whether through education, clinical resources, or new clinic support. We believe that strengthening engagement earlier in the process not only reinforces the values of Biote's relationship to its practitioner, but also helps support long-term clinic growth and retention. Our commercial outreach efforts further include driving competitive wins through new customer growth, expanding our clinician base, and improving retention through more active and consistent face-to-face sales force interaction. Clinical leadership also plays an important role in strengthening our practitioner relationships.

Bob PetersonInterim CEO and CFO

The value that Biote provides to our partners extends well beyond initial training and includes the ongoing education and clinical support that help practitioners make informed decisions to deliver consistent, high-quality care. Our Chief Medical Officer, Dr. Komal Bajaj, is leading our efforts to strengthen these resources and ensure we remain responsive to practitioners' needs. I'm pleased to have Dr. Bajaj join us today to discuss her priorities and how her work supports our commitment to clinical excellence and science and evidence-based education. I'll now turn the call to Dr. Bajaj.

Komal BajajChief Medical Officer

Thank you, Bob, and good afternoon, everyone. I appreciate the opportunity to discuss my priorities at Biote. Throughout my career, I have focused on helping clinicians apply medical knowledge in everyday practice. I joined Biote to help practitioners address unmet needs in hormone care and healthy aging, with the goal of improving the quality of life of our aging population. Working across Biote's broad network allows me to pursue that mission through practical clinical education and ongoing practitioner support. My priorities as Chief Medical Officer are centered on clinical excellence and the quality and consistency of care. That begins with understanding the questions practitioners encounter, the challenges they face in applying their training, and the resources that they will find most useful.

Komal BajajChief Medical Officer

I'm working closely with our team to use that feedback to shape our educational priorities and make our resources accessible, practical, and relevant, from initial training to continued development. Recurring questions help us identify where additional guidance would be most valuable and how we can make our clinical resources clearer and easier to use. Biote's commitment to science and evidence-based content is central to this work. We strive to have our education reflect available evidence, communicate limitations clearly, and evolve as the science develops. Maintaining that discipline is essential to sustaining practitioner trust. Ultimately, I want practitioners to view Biote as a continuing source of clinical expertise and support throughout their relationship with us. By helping them make informed clinical decisions, we can reinforce the value of belonging to Biote Network and help build lasting practitioner relationships.

Komal BajajChief Medical Officer

I recently joined more than 100 clinicians and world-class faculty at our advanced training event in Nashville, Tennessee. We believe that the discussions, interactions, and the education we provided on the future of healthcare set Biote apart as a leader in the industry, demonstrating our ongoing investment in clinical education and the support we provide to practitioners. I'm excited to be at Biote as we continue to expand our reach and help people with hormone optimization needs. With that, I'll turn the call back to Bob.

Bob PetersonInterim CEO and CFO

Thank you, Dr. Bajaj. Now I'll review our third quarter financial results. Unless otherwise noted, all quarterly financial comparisons in my prepared remarks are made against the third quarter of 2025. Revenue decreased 9.6% to $43.3 million. Procedure revenue declined 15.1% to $28.9 million due to the voluntary recall in January 2026, which delayed improvements in attrition and new clinic starts. We remain committed to restoring growth, with our immediate efforts centered on sales productivity and practitioner engagement. Dietary supplements revenue grew 7.3% to $12.0 million. The increase was primarily driven by continued growth in our e-commerce channel. Gross margin was 67.7% compared to 71.8%. The decrease was primarily the result of residual impacts from the voluntary recall, which led to increased use of lower-margin third-party pellets.

Bob PetersonInterim CEO and CFO

On a sequential basis, gross margin improved 231 basis points from the second quarter of 2026, as our mix of pellets sourced from third-party suppliers began to shift back to our internally manufactured pellets in the latter half of the third quarter. We anticipate further sequential improvement in gross margin due to efficiencies gained through our vertical integrated structure and as a greater percentage of our pellets are manufactured and shipped by Asteria Health. For perspective, as of today, Asteria Health has returned to pre-recall levels and will supply over 50% of our shipped pellets as compared to 30% in the second quarter of 2026 and over 50% in the fourth quarter of 2025. Selling, general, and administrative expenses increased 2.6% to $26.8 million. Relative to the second quarter of 2026, SG&A decreased by 20.8%, primarily reflecting reduced legal settlements and other legal-related expenses.

Bob PetersonInterim CEO and CFO

Net income was $0.6 million, and diluted earnings per share attributed to biote Corp. stockholders was $0.01, as compared to net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22. Net income for the third quarter of 2026 included a gain of $1.0 million due to the change in the fair value of the earnout liabilities and compared to a gain of $2.9 million in the third quarter of 2025. Adjusted EBITDA decreased to $5.1 million, with an Adjusted EBITDA margin of 11.7%. Cash flow provided by operations in the third quarter was $3.7 million. We continue to invest capital to broaden and improve our product and technology offerings. As of September 30, 2026, cash and cash equivalents were $8.9 million, as compared to $11.2 million as of June 30, 2026.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day